Purdue Pharma announced the launch of a new 7.5mcg/hour dosage strength of Butrans (buprenorphine) Transdermal System CIII, following its Food and Drug Administration (FDA) approval in July 2014. It is the first transdermal system to deliver seven days of buprenorphine.
Butrans is a Schedule III partial opioid agonist indicated for the management of pain severe enough to require daily, around-the clock, long-term opioid treatment for which alternative treatment options are inadequate in adults ≥18 years. Buprenorphine is a partial agonist at mu opioid receptors, an antagonist at kappa-opioid receptors, an agonist at delta-opioid receptors, and a partial agonist at ORL-1 (nociceptin) receptors. Its clinical actions result from binding to the opioid receptors.
The Butrans transdermal patch is also available in 5mcg/hour, 10mcg/hour, 15mcg/hour and 20mcg/hour strengths.
For more information call (888) 726-7535 or visit Butrans.com.